Zim Labs: consolidated loss widens YoY to ₹2.05 Cr despite 19% revenue growth, eases QoQ

Zim Laboratories' consolidated Q2 FY27 revenue from operations rose 18.9% YoY to ₹105.45 Cr (₹88.71 Cr in Q2 FY26) and 12.0% sequentially (₹94.18 Cr in Q1 FY27), but the group posted a net loss of ₹2.05 Cr — wider than the ₹0.42 Cr loss a year ago, even as it narrowed from the ₹4.02 Cr loss booked in Q1 FY27. Basic consolidated EPS was -₹0.38 versus -₹0.09 a year ago. Standalone results tell a sharper story: the standalone entity swung from a ₹0.12 Cr profit in Q2 FY26 to a ₹2.14 Cr loss this quarter, a materially different YoY trajectory than the consolidated numbers; with NCI negligible, the gap sits in subsidiary-level P&L performance rather than minority claims.

The operating margin (EBITDA/revenue) came in at 5.1%, down from 6.5% a year ago but up sharply from 2.6% in Q1 FY27 — the sequential expansion tracks lower other expenses as a share of revenue, while finance costs (₹3.94 Cr) and depreciation (₹6.53 Cr) stayed elevated on ongoing capex. Net margin was -1.9% versus -0.5% YoY and -4.2% QoQ. Revenue growth is running well ahead of management's FY27 base-case guidance of 10-15% given on the Q1 FY27 call (excluding EU-GMP impact) — H1 FY27 revenue grew ~24.4% YoY to ₹199.62 Cr — but the company gave no numeric FY27 margin guidance, so the continuing losses can't be benchmarked against a formal target; management had tied mid-teens EBITDA margins to a post-EU-GMP, FY28 event. No analyst consensus estimates for this quarter turned up in public searches, so vsStreet is unknown. No company press release accompanied this filing, leaving no management commentary to reconcile against the print.

The stock went into the print at ₹135.01, down 2.9% over the past month of trading.

During the quarter the company incorporated a wholly-owned subsidiary in Chile (Sept 18) and completed an investment in a step-down subsidiary (Sept 15), extending its international footprint alongside the enzyme/nutra capex management guided at ₹15-20 Cr; consolidated gross property, plant and equipment rose to ₹178.35 Cr from ₹156.43 Cr at FY26-end. Heading into Q3, the readthrough is a business growing revenue faster than guided while still working through cost pressure that has kept it loss-making for a second straight quarter, with the EU-GMP approval timeline remaining the swing factor for the FY28 margin structure management has laid out.